Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024)
Zentalis Pharmaceuticals' (ZNTL) quarterly Income from Non-Controlling Interests came in at -$28000.0 in Q1 2024, up 34.88% year-on-year from -$20758.6 in Q2 2023, and down 27.27% quarter-over-quarter from -$22000.0 in Q4 2023.
Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024) Analysis & Trends
Zentalis Pharmaceuticals' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$28000.0 for Q1 2024.
- On a quarterly basis, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0 in Q1 2024; TTM through Dec 2024 was -$28000.0, a 75.44% increase from a year earlier, with the FY2024 full-year figure at -$28000.0, up 75.44% from the prior year.
- Income from Non-Controlling Interests eased to -$28000.0 in Q1 2024 per ZNTL's latest filing, from -$22000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$12000.0 in Q3 2023 and bottomed at -$6.3 million in Q3 2021.
- The 5-year median for Income from Non-Controlling Interests is -$53000.0 (2020), against an average of -$501411.8.
- Across the five-year window, Income from Non-Controlling Interests plunged 5628.18% in 2021 and jumped 98.43% in 2022, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$53000.0 in 2020, then surged by 32.08% to -$36000.0 in 2021, then surged by 63.89% to -$13000.0 in 2022, then slumped by 69.23% to -$22000.0 in 2023, then slipped by 27.27% to -$28000.0 in 2024.
- Per Business Quant, the three latest ZNTL Income from Non-Controlling Interests figures stand at -$28000.0 (Q1 2024), -$22000.0 (Q4 2023), and -$12000.0 (Q3 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 302.14 Mn | 302.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | -37,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -99,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -160,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | -6.30 Mn |
| Jun 30, 2021 | -488,000.00 |
| Mar 31, 2021 | -543,000.00 |
| Dec 31, 2020 | -53,000.00 |
| Sep 30, 2020 | -110,000.00 |
| Jun 30, 2020 | -435,000.00 |
| Mar 31, 2020 | -109,000.00 |
| Dec 31, 2019 | -40,000.00 |
| Sep 30, 2019 | -228,000.00 |
| Jun 30, 2019 | -127,000.00 |